Pure Global
NCT05446532

Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes

Characteristics of Hepatitis B HBsAg & HBsAc Carriers Simultaneously
Corporacion Parc Tauli·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis B
Study type
Observational
Sponsor & location
Primary sponsor
Corporacion Parc Tauli
Location
Sabadell, Spain
Timeline & enrollment
Phase
N/A
Start date
Jun 15, 2022
End date
Dec 31, 2022
Enrollment
120 participants
Primary outcome

prevalence concomitant HBsAg and HBsAc markers

Summary

HBV infection is a dynamic process with complex interactions between virus replication and
 the host's immune response. The appearance of anti-HBs after HBV infection generally
 indicates recovery and immunity to HBV1 infection. However, there are several published
 studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the
 marker of functional cure (HBsAc +). There are contradictory studies on whether the
 coexistence of HBsAg/HBsAc implies a different clinical course.

ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05446532
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05446532 through Pure Global AI's free database. This phase not specified trial is sponsored by Corporacion Parc Tauli and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.